Grünenthal uses its own and third-party cookies to improve the browsing experience, offer personalized content and improve its services. We use analytics scripts which set tracking cookies. More details and information can be found in our Data Privacy Statement – please refer to this to adjust your settings for website analytics tracking (e.g. enable/disable). By closing this window you agree to our standard Terms of Use.

I'm ok with this


Updates & Features

CGRP Antibodies for the Treatment of Migraine

October 2018

Can the first migraine-specific therapeutics change the treatment landscape?

PainSolve Editorial Team

State of the art in migraine

Migraine is one of the most prevalent and disabling disorders in the world, yet, until recently, no preventive treatments in clinical use were developed specifically for migraine. In May 2018, the FDA approved the first in a new class of drugs designed for the preventive treatment of migraine in adults.1 Erenumab, administered as a once-monthly self-injection, acts by blocking the activity of calcitonin gene-related peptide (CGRP), a molecule that spikes during migraine attacks.1,2 Three other CGRP-targeted monoclonal antibodies are also under investigation for their potential in the treatment of migraine: galcanezumab, eptinezumab and fremanezumab.3


Share this with:

These are external links and will open in a new window